This trial is testing a new drug to treat chordoma, a type of cancer. The target patient population is any chordoma patient 18 years of age with locally unresectable disease or metastatic disease.
1 Primary · 0 Secondary · Reporting Duration: through study completion, an average of 1 year
Experimental Treatment
15 Total Participants · 1 Treatment Group
Primary Treatment: Cetuximab · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: